| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/07/2006 | EP1421075B1 Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv |
| 06/07/2006 | EP1411899A4 Taste masking composition |
| 06/07/2006 | EP1383523B1 Agent for treating diabetes mellitus |
| 06/07/2006 | EP1265630B1 Use of insulin for the treatment of cartilagenous disorders |
| 06/07/2006 | EP1200039B1 Emulsifier-free finely dispersed water-in-oil-type systems |
| 06/07/2006 | EP1165112B1 Modulators of polysaccharides and uses thereof |
| 06/07/2006 | EP1162969B1 use of dipeptidyl peptidase IV inhibitors fOR IMPROVING FERTILITY |
| 06/07/2006 | EP1124592B1 Textured and porous silicone rubber |
| 06/07/2006 | EP1107794B1 Therapeutic compositions for the treatment of mucus hypersecretion |
| 06/07/2006 | EP1104307B1 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| 06/07/2006 | EP1071463B1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 06/07/2006 | EP1068870B1 Antitumor agents |
| 06/07/2006 | EP0772437B1 Compositions for delivery of genetic material |
| 06/07/2006 | CN1784243A A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| 06/07/2006 | CN1784235A Fortifier |
| 06/07/2006 | CN1784232A Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use |
| 06/07/2006 | CN1784219A Ultraviolet-shielding type patch |
| 06/07/2006 | CN1781920A Polycyclic guanine phosphodiesterase v inhibitor |
| 06/07/2006 | CN1781554A Compound medicine for predicting ACEI pressure reducing medicine effect |
| 06/07/2006 | CN1781545A Method for extracting herbal medicine |
| 06/07/2006 | CN1781477A Composite capsule for stomach intestine and its preparing method and use |
| 06/07/2006 | CN1258563C Highly-neutralized ethylene copolymers and their use in golf balls |
| 06/07/2006 | CN1258551C Preparing method of degradable polymer |
| 06/07/2006 | CN1258379C Botulinum toxin pharmaceutical composition |
| 06/07/2006 | CN1258362C Use of substituted acryloyl stallimycin derivatives in treatment of tumors associated with high levels of glutathione |
| 06/07/2006 | CN1258353C Cosmetic and pharmaceutical composition and its use |
| 06/07/2006 | CN1258327C 液体抗微生物组合物 Liquid anti-microbial composition |
| 06/06/2006 | US7057046 Lactam glycogen phosphorylase inhibitors and method of use |
| 06/06/2006 | US7057013 TGFβ1 inhibitor peptides |
| 06/06/2006 | US7056949 Liver disorders, dietetics; weight ratio of glycerides to diglycerides |
| 06/06/2006 | US7056944 Pyrazole compositions useful as inhibitors of erk |
| 06/06/2006 | US7056936 Synergistic combination |
| 06/06/2006 | US7056917 Prevent drug resistance |
| 06/06/2006 | US7056909 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 06/06/2006 | US7056906 Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| 06/06/2006 | US7056887 Treatment of acute coronary syndrome with GLP-1 |
| 06/06/2006 | US7056886 GLP-2 formulations |
| 06/06/2006 | US7056885 Fibroblast growth factor and nucleic acids encoding same |
| 06/06/2006 | US7056735 Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) |
| 06/06/2006 | US7056720 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
| 06/06/2006 | US7056712 Administering to the individual therapeutically effective amount of human acid alpha-glucosidase at regular interval for therapy of glycogen storage disease type II |
| 06/06/2006 | US7056704 RNA interference mediating small RNA molecules |
| 06/06/2006 | US7056695 TNF-α variants |
| 06/06/2006 | US7056692 Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase beta/zeta |
| 06/06/2006 | US7056655 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| 06/06/2006 | US7056550 priming the device (e.g., a stent) by dip coating with a hexafluoropropylene-vinylidene fluoride polymer prepared by batch emulsion polymerization; spin coating with a polymer-drug mixture; and drying in a vacuum oven for sixteen hours at a temperature at 15-60 degrees C.; improved biocompatibility |
| 06/06/2006 | US7056524 Methods of hydrating mucosal surfaces |
| 06/06/2006 | US7056521 Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| 06/06/2006 | US7056516 Comprises nucleotide sequences coding caspase 8 inhibitory protein for use in the treatment of alzheimer's, parkinson's, arthritic, septic, cardiovascular, inflammatory, osteoporotic and ischemic reperfusion injuries/disorders |
| 06/06/2006 | US7056509 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents |
| 06/06/2006 | US7056508 Receptor-type phosphotyrosine phosphatase-kappa antibodies |
| 06/06/2006 | US7056500 Polymer conjugates of opioid antagonists |
| 06/06/2006 | CA2457852C Multivesicular emulsion topical delivery systems |
| 06/06/2006 | CA2417686C Manufacture of oral dosage forms delivering both immediate release and sustained release drugs |
| 06/06/2006 | CA2133080C Calanolide antiviral compounds, compositions and uses thereof |
| 06/01/2006 | WO2006057460A1 Nitrogen-containing fused ring compound and use thereof |
| 06/01/2006 | WO2006057375A1 Medicinal preparation for external use |
| 06/01/2006 | WO2006057270A1 Nitrogeneous tricyclic compound |
| 06/01/2006 | WO2006057209A1 Pharmaceutical composition having action of lowering blood free fatty acid |
| 06/01/2006 | WO2006057154A1 Efficacy enhancing agent for anticancer drug |
| 06/01/2006 | WO2006057152A1 Therapeutic agent for diabetes comprising protease-inhibiting compound |
| 06/01/2006 | WO2006036484A3 Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations |
| 06/01/2006 | WO2006031467A9 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| 06/01/2006 | WO2006031337A3 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 06/01/2006 | WO2005023190A3 Treatment for cd5+ b cell lymphoma |
| 06/01/2006 | WO2004066932A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 06/01/2006 | WO2004004656A3 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 06/01/2006 | WO2003025542A3 Immune response associated proteins |
| 06/01/2006 | US20060116627 Compositions, kits, methods, and apparatus for transvascular delivery of a composition to an extravascular tissue of a mammal |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116403 Therapeutic target and uses thereof |
| 06/01/2006 | US20060116395 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease |
| 06/01/2006 | US20060116328 Combined use of carnosinase inhibitor with l-carnosines and composition |
| 06/01/2006 | US20060115869 Uses of carbamoyl phosphate synthetas for the diagnosis of inflammatory diseases and sepsis |
| 06/01/2006 | US20060115813 Intracellular signaling molecules |
| 06/01/2006 | US20060115530 Gastric acid secretion inhibiting composition |
| 06/01/2006 | DE19901687B4 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung Opioid analgesics controlled release |
| 06/01/2006 | CA2526541A1 Novel biomaterial drug delivery and surface modification compositions |
| 05/31/2006 | EP1661892A1 Condensed ring compound and use thereof |
| 05/31/2006 | EP1661881A2 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 05/31/2006 | EP1661583A1 External preparation for percutaneous administration containing nonsteroidal anti-inflammatory analgesic |
| 05/31/2006 | EP1661581A1 Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
| 05/31/2006 | EP1661580A1 Remedy for cartilage-related diseases |
| 05/31/2006 | EP1661571A2 Medicaments for preventing intervention-associated stenosis following non-bypass, invasive interventions |
| 05/31/2006 | EP1660475A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 05/31/2006 | EP1660473A2 Xanthones, thioxanthones and acridinones as dna-pk inhibitors |
| 05/31/2006 | EP1660434A1 Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition |
| 05/31/2006 | EP1660428A1 Ppar modulators |
| 05/31/2006 | EP1660183A2 Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4) |
| 05/31/2006 | EP1660132A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor |
| 05/31/2006 | EP1660131A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 05/31/2006 | EP1660130A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression |
| 05/31/2006 | EP1660122A2 Immunostimulatory combinations and treatments |
| 05/31/2006 | EP1660116A1 Method of treating viral infections |
| 05/31/2006 | EP1660100A1 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
| 05/31/2006 | EP1660085A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 05/31/2006 | EP1660078A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions. |
| 05/31/2006 | EP1660076A1 Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1 |
| 05/31/2006 | EP1660059A1 Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars) |
| 05/31/2006 | EP1660057A2 Combination therapy for the treatment of ocular neovascular disorders |